Publicaciones en las que colabora con Salvador Resino García (58)

2024

  1. IgG antibody levels against the SARS-CoV-2 spike protein in mother–child dyads after COVID-19 vaccination

    Infection, Vol. 52, Núm. 3, pp. 813-824

  2. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study

    Journal of Infection and Public Health, Vol. 17, Núm. 7

2023

  1. Antibody levels to SARS-CoV-2 spike protein in mothers and children from delivery to six months later

    Birth, Vol. 50, Núm. 2, pp. 418-427

2016

  1. Fifteen-year trends in the prevalence of diabetes among hospitalized HIV-infected patients in Spain (1997-2012)

    PLoS ONE, Vol. 11, Núm. 9

  2. Trends in epidemiology of COPD in HIV-Infected patients in Spain (1997-2012)

    PLoS ONE, Vol. 11, Núm. 11

2011

  1. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy

    HIV Medicine, Vol. 12, Núm. 1, pp. 54-60

  2. Cardiovascular risk markers are increased in HIV-infected children with lipodystrophy syndrome

    Journal of Infection

2010

  1. Opportunistic infections and organ-specific diseases in HIV-1-infected children: A cohort study (1990-2006)

    HIV Medicine, Vol. 11, Núm. 4, pp. 245-252

2008

  1. Immunological recovery and metabolic disorders in severe immunodeficiency HIV type 1-infected children on highly active antiretroviral therapy

    AIDS Research and Human Retroviruses, Vol. 24, Núm. 12, pp. 1477-1484

  2. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 1, pp. 183-190

2007

  1. Carga viral plasmática en niños infectados por el virus de la inmunodeficiencia humana que reciben tratamiento antirretroviral de gran actividad

    Medicina Clinica, Vol. 128, Núm. 2, pp. 49-51

  2. Long-term response to highly active antiretroviral therapy in human immunodeficiency virus and hepatitis C virus coinfected children: 6 Years of follow-up

    Pediatric Infectious Disease Journal, Vol. 26, Núm. 11, pp. 1061-1064

  3. Slow progression of human immunodeficiency virus and hepatitis C virus disease in a cohort of coinfected children

    Pediatric Infectious Disease Journal, Vol. 26, Núm. 9, pp. 846-849

2006

  1. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency [4]

    Journal of Antimicrobial Chemotherapy

  2. CD4+ T-cell immunodeficiency is more dependent on immune activation than viral load in HIV-infected children on highly active antiretroviral therapy

    Journal of Acquired Immune Deficiency Syndromes, Vol. 42, Núm. 3, pp. 269-276

  3. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children

    BMC Infectious Diseases, Vol. 6

  4. Impact of long-term viral suppression in CD4+ recovery of HIV-children on Highly Active Antiretroviral Therapy

    BMC Infectious Diseases, Vol. 6

  5. Interleukin-7 levels before highly active antiretroviral therapy may predict CD4+ T-cell recovery and virological failure in HIV-infected children [5]

    Journal of Antimicrobial Chemotherapy

  6. La terapia combinada puede ser tan efectiva como la terapia antirretroviral de alta eficacia en el control de la carga viral en niños con un sistema inmunitario conservado

    Acta pediátrica española, Vol. 64, Núm. 8, pp. 377

  7. La terapia combinada puede ser tan efectiva como la terapia antirretroviral de alta eficacia en el control de la carga viral en niños con un sistema inmunitario conservado

    Acta Pediatrica Espanola, Vol. 64, Núm. 8, pp. 377-382